Legend Biotech Announces Preliminary Q4 2025 CARVYKTI Sales of Approximately $555 Million

Legend Biotech ( (LEGN) ) has shared an update.

On January 21, 2026, Legend Biotech reported that its multiple myeloma cell therapy CARVYKTI generated approximately $555 million in net trade sales for the quarter ended December 31, 2025, based on preliminary data provided by collaboration partner Janssen. The company noted that this sales figure is preliminary and subject to the completion of Legend Biotech’s year-end financial statements and associated accounting determinations, and it has not yet been audited or reviewed by the company’s independent registered public accountants, underscoring that final revenue and gross profit recognition for the quarter could differ from this initial estimate.

The most recent analyst rating on (LEGN) stock is a Buy with a $66.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.

Spark’s Take on LEGN Stock

According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.

Legend Biotech’s strong revenue growth and strategic advancements in CARVYKTI are overshadowed by significant profitability and cash flow challenges. The technical indicators suggest bearish momentum, and the valuation metrics reflect ongoing financial struggles. While the earnings call provides a positive outlook, the company’s current financial health remains a concern.

To see Spark’s full report on LEGN stock, click here.

More about Legend Biotech

Legend Biotech Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies, including CAR-T treatments, with operations in the United States and collaborations with major pharmaceutical partners such as Janssen to market its oncology products.

Average Trading Volume: 2,091,658

Technical Sentiment Signal: Sell

Current Market Cap: $4.09B

Learn more about LEGN stock on TipRanks’ Stock Analysis page.